On March 27 at 11am EST, investors are gathering together to discuss innovation in cardiology and explore a category-redefining company - CoRisma’s product development led by a leading cardiothoracic surgeon at Yale University's School of Medicine and a highly regarded industry thought leader.

The company is developing a transformational heart pump platform that will truly be a disruptor to the mechanical circulatory support (MCS) industry:  a transcatheter universal platform, agnostic to indications including both short duration episodes (i.e., High Risk PCI, Cardiogenic Shock) and long duration episodes (i.e., Bridge to Transplant, Destination Therapy).  The innovative VegaTeq product platform represents the world's first universal, wireless, tether-free percutaneous pump and is positioned to disrupt a multi-billion dollar market currently dominated by aging legacy architectures.

Strong IP portfolio with a solid patent moat around wireless power and expandable impeller geometry and has already conducted a successful Series A raise ($12M). 

$2M in bridge financing not only to maintain the VegaTeq platform development momentum but also to trigger a $12M non-dilutive development contract with the lead Series A investor.  The funds will be used to finalize the clinical prototype/design freeze, to begin GLP-grade animal studies, and to secure FDA Q-submission to accelerate the regulatory process. 

The bridge financing ensures CoRISMA will have the necessary runway to reach the critical milestones required in advance of a highly anticipated Series B raise.